Bioequivalence Study of Rosuvastatin 10 mg in Healthy Volunteers

The primary objective of this study is to evaluate the **bio-equivalence** of Rosuvastatin 10 mg in healthy volunteers. This is clinically relevant as establishing bio-equivalence ensures that the generic formulation of Rosuvastatin is therapeutically equivalent to the brand-name drug, providing the same efficacy and safety profile. This is crucial for maintaining consistent treatment outcomes in patients who are prescribed this medication for managing cholesterol levels.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants includes individuals from the categories of 18-64 years and 65 years and older. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. The selection of the trial population does not specify any particular lifestyle considerations such as diet, physical activity, or habits. Key inclusion or exclusion criteria have not been detailed by the sponsor.

The clinical trial is designed to evaluate the **bio-equivalence** of Rosuvastatin 10 mg in **healthy volunteers**. This study is a Phase 2 trial, which is categorized as a controlled, randomized, and double-blind study. The trial is expected to commence recruitment on August 1, 2024, and is projected to conclude by June 30, 2025. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by the study protocol.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. This visit ensures that only suitable candidates are enrolled in the trial. Following successful inclusion, participants will undergo a series of follow-up visits. These visits are scheduled at regular intervals to monitor the participants' health status, adherence to the study protocol, and any potential adverse effects. The end-of-study visit marks the conclusion of the participant's involvement, where final assessments are conducted to gather comprehensive data on the study's outcomes.

Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial's design and procedures are structured to ensure the safety and well-being of participants while maintaining the integrity of the data collected. The study's methodology and design are aligned with regulatory standards to ensure the reliability and validity of the trial results.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered in this context.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to commence recruitment on August 1, 2024, with an estimated completion date of June 30, 2025. The efficacy assessment will be conducted through a series of planned evaluations, although specific parameters or endpoints for efficacy evaluation are not detailed in the provided data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The methods and tools for measuring efficacy, as well as the specific timepoints for these assessments, are not specified in the available information. The trial will adhere to rigorous standards typical of Phase 2 studies to ensure the reliability and validity of the efficacy data collected.